{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:17:28Z","timestamp":1763201848428},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T00:00:00Z","timestamp":1407196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s11095-014-1467-3","type":"journal-article","created":{"date-parts":[[2014,8,4]],"date-time":"2014-08-04T21:48:38Z","timestamp":1407188918000},"page":"362-374","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of Piroxicam Plus Cisplatin-Loaded PLGA Nanoparticles in Inducing Apoptosis in Mesothelioma Cells"],"prefix":"10.1007","volume":"32","author":[{"given":"Ciro","family":"Menale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Favicchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Aruta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Nicolucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Barba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiano Gustavo","family":"Mita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Crispi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Diano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,5]]},"reference":[{"issue":"7463","key":"1467_CR1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/bmj.38176.444745.63","volume":"329","author":"T Treasure","year":"2004","unstructured":"Treasure T. The learning curve. BMJ. 2004;329(7463):424.","journal-title":"BMJ"},{"issue":"1","key":"1467_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/156800910790980232","volume":"10","author":"S Crispi","year":"2010","unstructured":"Crispi S, Cardillo I, Spugnini EP, Citro G, Menegozzo S, Baldi A. Biological agents involved in malignant mesothelioma: relevance as biomarkers or therapeutic targets. Curr Cancer Drug Targets. 2010;10(1):19\u201326.","journal-title":"Curr Cancer Drug Targets"},{"issue":"4","key":"1467_CR3","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1378\/chest.126.4.1318","volume":"126","author":"M Pistolesi","year":"2004","unstructured":"Pistolesi M, Rusthoven J. Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies. Chest. 2004;126(4):1318\u201329.","journal-title":"Chest"},{"issue":"14","key":"1467_CR4","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1467_CR5","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1002\/cncr.11405","volume":"97","author":"AG Favaretto","year":"2003","unstructured":"Favaretto AG, Aversa SM, Paccagnella A, Manzini Vde P, Palmisano V, Oniga F, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer. 2003;97(11):2791\u20137.","journal-title":"Cancer"},{"issue":"20 Pt 1","key":"1467_CR6","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.1158\/1078-0432.CCR-06-1056","volume":"12","author":"EP Spugnini","year":"2006","unstructured":"Spugnini EP, Cardillo I, Verdina A, Crispi S, Saviozzi S, Calogero R, et al. Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res. 2006;12(20 Pt 1):6133\u201343.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1467_CR7","doi-asserted-by":"crossref","first-page":"e23569","DOI":"10.1371\/journal.pone.0023569","volume":"6","author":"A Baldi","year":"2011","unstructured":"Baldi A, Piccolo MT, Boccellino MR, Donizetti A, Cardillo I, La Porta R, et al. Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS ONE. 2011;6(8):e23569.","journal-title":"PLoS ONE"},{"issue":"8","key":"1467_CR8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573\u201384.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1467_CR9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","volume":"4","author":"D Wang","year":"2005","unstructured":"Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307\u201320.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"1467_CR10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","volume":"7","author":"RK Jain","year":"2010","unstructured":"Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653\u201364.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"1467_CR11","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s11095-011-0600-9","volume":"29","author":"Y Li","year":"2012","unstructured":"Li Y, Lim S, Ooi CP. Fabrication of cisplatin-loaded poly(lactide-co-glycolide) composite microspheres for osteosarcoma treatment. Pharm Res. 2012;29(3):756\u201369.","journal-title":"Pharm Res"},{"issue":"1\u20132","key":"1467_CR12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijpharm.2007.04.031","volume":"342","author":"Y Dong","year":"2007","unstructured":"Dong Y, Feng SS. Poly(D, L-lactide-co-glycolide) (PLGA) nanoparticles prepared by high pressure homogenization for paclitaxel chemotherapy. Int J Pharm. 2007;342(1\u20132):208\u201314.","journal-title":"Int J Pharm"},{"key":"1467_CR13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.cocis.2010.11.005","volume":"16","author":"C Grama","year":"2011","unstructured":"Grama C, Ankola D, MNV RK. Poly(lactide-co-glycolide) nanoparticles for peroral delivery of bioactives. Curr Opin Colloid Interface Sci. 2011;16:238\u201345.","journal-title":"Curr Opin Colloid Interface Sci"},{"issue":"2","key":"1467_CR14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2217\/17435889.2.2.219","volume":"2","author":"T Betancourt","year":"2007","unstructured":"Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine. 2007;2(2):219\u201332.","journal-title":"Nanomedicine"},{"issue":"9","key":"1467_CR15","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2217\/nnm.11.44","volume":"6","author":"A Murugeshu","year":"2011","unstructured":"Murugeshu A, Astete C, Leonardi C, Morgan T, Sabliov CM. Chitosan\/PLGA particles for controlled release of alpha-tocopherol in the GI tract via oral administration. Nanomedicine. 2011;6(9):1513\u201328.","journal-title":"Nanomedicine"},{"issue":"5","key":"1467_CR16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2217\/nnm.12.134","volume":"8","author":"PM Valencia","year":"2013","unstructured":"Valencia PM, Pridgen EM, Perea B, Gadde S, Sweeney C, Kantoff PW, et al. Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine. 2013;8(5):687\u201398.","journal-title":"Nanomedicine"},{"issue":"6","key":"1467_CR17","first-page":"2425","volume":"33","author":"KK Vangara","year":"2013","unstructured":"Vangara KK, Liu JL, Palakurthi S. Hyaluronic acid-decorated PLGA-PEG nanoparticles for targeted delivery of SN-38 to ovarian cancer. Anticancer Res. 2013;33(6):2425\u201334.","journal-title":"Anticancer Res"},{"issue":"4","key":"1467_CR18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/cgt.2013.12","volume":"20","author":"L Zou","year":"2013","unstructured":"Zou L, Song X, Yi T, Li S, Deng H, Chen X, et al. Administration of PLGA nanoparticles carrying shRNA against focal adhesion kinase and CD44 results in enhanced antitumor effects against ovarian cancer. Cancer Gene Ther. 2013;20(4):242\u201350.","journal-title":"Cancer Gene Ther"},{"key":"1467_CR19","doi-asserted-by":"crossref","unstructured":"Sadhukha T, Prabha S. Encapsulation in Nanoparticles Improves Anti-cancer Efficacy of Carboplatin. AAPS PharmSciTech. 2014","DOI":"10.1208\/s12249-014-0139-2"},{"issue":"6","key":"1467_CR20","doi-asserted-by":"crossref","first-page":"e98455","DOI":"10.1371\/journal.pone.0098455","volume":"9","author":"Q Tang","year":"2014","unstructured":"Tang Q, Wang Y, Huang R, You Q, Wang G, Chen Y, et al. Preparation of anti-tumor nanoparticle and its inhibition to peritoneal dissemination of colon cancer. PLoS ONE. 2014;9(6):e98455.","journal-title":"PLoS ONE"},{"issue":"3","key":"1467_CR21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2174\/187221112802652606","volume":"6","author":"E Pinon-Segundo","year":"2012","unstructured":"Pinon-Segundo E, Nava-Arzaluz MG, Lechuga-Ballesteros D. Pharmaceutical polymeric nanoparticles prepared by the double emulsion- solvent evaporation technique. Recent pat on drug deliv & formulation. 2012;6(3):224\u201335.","journal-title":"Recent pat on drug deliv & formulation"},{"issue":"7","key":"1467_CR22","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1007\/s11095-009-9889-z","volume":"26","author":"C Jin","year":"2009","unstructured":"Jin C, Bai L, Wu H, Song W, Guo G, Dou K. Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells. Pharm Res. 2009;26(7):1776\u201384.","journal-title":"Pharm Res"},{"key":"1467_CR23","unstructured":"Ranall MV, Gabrielli BG, Gonda TJ. High-content imaging of neutral lipid droplets with 1,6-diphenylhexatriene. BioTechniques. 2011;51(1):35\u20136, 8\u201342."},{"key":"1467_CR24","doi-asserted-by":"crossref","unstructured":"Strober W. Trypan blue exclusion test of cell viability. Curr Protoc Immunol. 2001; Appendix 3: Appendix 3B.","DOI":"10.1002\/0471142735.ima03bs21"},{"issue":"4","key":"1467_CR25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0092-8674(00)80434-1","volume":"91","author":"P Li","year":"1997","unstructured":"Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1\/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91(4):479\u201389.","journal-title":"Cell"},{"key":"1467_CR26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.6000\/1929-2279.2012.01.02.5","volume":"1","author":"MT Piccolo","year":"2012","unstructured":"Piccolo MT, Crispi S. The dual role played by p21 May influence the apoptotic or anti-apoptotic fate in cancer. J of Cancer Res Updat. 2012;1:189\u2013202.","journal-title":"J of Cancer Res Updat"},{"issue":"5","key":"1467_CR27","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i5.20","volume":"21","author":"I Bala","year":"2004","unstructured":"Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21(5):387\u2013422.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"1","key":"1467_CR28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/0192623307310946","volume":"36","author":"EM Merisko-Liversidge","year":"2008","unstructured":"Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol. 2008;36(1):43\u20138.","journal-title":"Toxicol Pathol"},{"issue":"2","key":"1467_CR29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/IJN.S596","volume":"3","author":"WH Jong De","year":"2008","unstructured":"De Jong WH, Borm PJ. Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008;3(2):133\u201349.","journal-title":"Int J Nanomedicine"},{"key":"1467_CR30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-9966-27-6","volume":"27","author":"EP Spugnini","year":"2008","unstructured":"Spugnini EP, Crispi S, Scarabello A, Caruso G, Citro G, Baldi A. Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations. J of exp & clin cancer res : CR. 2008;27:6.","journal-title":"J of exp & clin cancer res : CR"},{"issue":"6","key":"1467_CR31","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1021\/mp800072e","volume":"5","author":"Y Gao","year":"2008","unstructured":"Gao Y, Chen L, Gu W, Xi Y, Lin L, Li Y. Targeted nanoassembly loaded with docetaxel improves intracellular drug delivery and efficacy in murine breast cancer model. Mol Pharm. 2008;5(6):1044\u201354.","journal-title":"Mol Pharm"},{"issue":"10","key":"1467_CR32","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1023\/A:1020404615898","volume":"19","author":"M Huang","year":"2002","unstructured":"Huang M, Ma Z, Khor E, Lim LY. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm Res. 2002;19(10):1488\u201394.","journal-title":"Pharm Res"},{"issue":"1\u20132","key":"1467_CR33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ijpharm.2012.07.050","volume":"436","author":"L Mo","year":"2012","unstructured":"Mo L, Hou L, Guo D, Xiao X, Mao P, Yang X. Preparation and characterization of teniposide PLGA nanoparticles and their uptake in human glioblastoma U87MG cells. Int J Pharm. 2012;436(1\u20132):815\u201324.","journal-title":"Int J Pharm"},{"issue":"1","key":"1467_CR34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1124\/jpet.302.1.8","volume":"302","author":"BS Cummings","year":"2002","unstructured":"Cummings BS, Schnellmann RG. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. The J of pharmacol and exp ther. 2002;302(1):8\u201317.","journal-title":"The J of pharmacol and exp ther"},{"issue":"9","key":"1467_CR35","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.4049\/jimmunol.169.9.4805","volume":"169","author":"C Ferraro-Peyret","year":"2002","unstructured":"Ferraro-Peyret C, Quemeneur L, Flacher M, Revillard JP, Genestier L. Caspase-independent phosphatidylserine exposure during apoptosis of primary T lymphocytes. J Immunol. 2002;169(9):4805\u201310.","journal-title":"J Immunol"},{"key":"1467_CR36","doi-asserted-by":"crossref","unstructured":"el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75(4):817\u201325.","DOI":"10.1016\/0092-8674(93)90500-P"},{"issue":"8","key":"1467_CR37","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nrc864","volume":"2","author":"KH Vousden","year":"2002","unstructured":"Vousden KH, Lu X. Live or let die: the cell\u2019s response to p53. Nat Rev Cancer. 2002;2(8):594\u2013604.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1467_CR38","doi-asserted-by":"crossref","first-page":"e25433","DOI":"10.1371\/journal.pone.0025433","volume":"6","author":"L Cheng","year":"2011","unstructured":"Cheng L, Jin C, Lv W, Ding Q, Han X. Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. PLoS ONE. 2011;6(9):e25433.","journal-title":"PLoS ONE"},{"issue":"1","key":"1467_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2006.12.017","volume":"67","author":"EC Gryparis","year":"2007","unstructured":"Gryparis EC, Hatziapostolou M, Papadimitriou E, Avgoustakis K. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells. Eur J Pharm Biopharm. 2007;67(1):1\u20138.","journal-title":"Eur J Pharm Biopharm"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-014-1467-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-014-1467-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-014-1467-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T18:35:03Z","timestamp":1689446103000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-014-1467-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,5]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["1467"],"URL":"https:\/\/doi.org\/10.1007\/s11095-014-1467-3","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,5]]}}}